{"protocolSection":{"identificationModule":{"nctId":"NCT03303625","orgStudyIdInfo":{"id":"CR108371"},"secondaryIdInfos":[{"id":"2017-001345-27","type":"EUDRACT_NUMBER"},{"id":"VAC18194RSV2001","type":"OTHER","domain":"Janssen Vaccines & Prevention B.V."},{"id":"2017","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2017"}],"organization":{"fullName":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age","officialTitle":"A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age, RSV-seropositive Toddlers 12 to 24 Months of Age"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-11-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-04-21","type":"ACTUAL"},"completionDateStruct":{"date":"2020-04-21","type":"ACTUAL"},"studyFirstSubmitDate":"2017-10-03","studyFirstSubmitQcDate":"2017-10-03","studyFirstPostDateStruct":{"date":"2017-10-06","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-04-19","resultsFirstSubmitQcDate":"2023-05-30","resultsFirstPostDateStruct":{"date":"2023-06-23","type":"ACTUAL"},"dispFirstSubmitDate":"2021-04-20","dispFirstPostDateStruct":{"date":"2023-06-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-22","lastUpdatePostDateStruct":{"date":"2025-05-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Vaccines & Prevention B.V.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety and tolerability of an intramuscular regimen of two doses (1\\*10\\^11 viral particles \\[vp\\]) of an investigational respiratory syncytial virus (RSV) vaccine candidate (adenovirus serotype 26 respiratory syncytial virus pre-fusion conformation stabilized F protein \\[pre-F\\] \\[Ad26.RSV.preF\\]) in adults aged 18 to 50 years and RSV-seropositive toddlers aged 12 to 24 months.","detailedDescription":"The study, designed to assess the safety and tolerability of two doses given one month apart of Ad26.RSV.preF, an investigational RSV vaccine candidate based on a Ad26 vector expressing the RSV F protein, will be conducted in a double blinded manner. The study will be divided in two sequential cohorts: cohort 0 (18-50 year-old adults) and cohort 1 (12-24 month-old RSV seropositive toddlers). The vaccine safety will be monitored by reporting solicited and unsolicited adverse events (AEs) and all serious adverse events (SAEs). The data will be reviewed by an independent data monitoring committee (IDMC) to assess safety data and to ensure the continuing safety of the participants enrolled in this study. The safety will be monitored throughout the study."},"conditionsModule":{"conditions":["Respiratory Syncytial Viruses","Respiratory Tract Infections"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":48,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 0: Adults (Ad26.RSV.preF)","type":"EXPERIMENTAL","description":"Participants aged greater than or equal to (\\>=) 18 to lesser than or equal to (\\<=) 50 years will receive vector Ad26.RSV.preF at 1\\*10\\^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.","interventionNames":["Biological: Ad26.RSV.preF (1*10^11 vp)"]},{"label":"Cohort 0: Adults (Placebo)","type":"PLACEBO_COMPARATOR","description":"Participants aged \\>= 18 to \\<= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.","interventionNames":["Drug: Placebo"]},{"label":"Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)","type":"EXPERIMENTAL","description":"RSV seropositive participants aged \\>=12 to \\<=24 months will receive Ad26.RSV.preF at 5\\*10\\^10 vp via IM route (Group 3) on Day 1 and 29.","interventionNames":["Biological: Ad26.RSV.preF (5*10^10 vp)"]},{"label":"Cohort 1: RSV seropositive Toddlers (Placebo)","type":"PLACEBO_COMPARATOR","description":"RSV seropositive participants aged \\>= 12 to \\<= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.RSV.preF (1*10^11 vp)","description":"Participants will receive two doses of 0.5 milliliter (mL) (1\\*10\\^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.","armGroupLabels":["Cohort 0: Adults (Ad26.RSV.preF)"],"otherNames":["JNJ-64400141"]},{"type":"BIOLOGICAL","name":"Ad26.RSV.preF (5*10^10 vp)","description":"RSV seropositive participants will receive two doses of 0.25 mL (5\\*10\\^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.","armGroupLabels":["Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)"],"otherNames":["JNJ-64400141"]},{"type":"DRUG","name":"Placebo","description":"Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.","armGroupLabels":["Cohort 0: Adults (Placebo)","Cohort 1: RSV seropositive Toddlers (Placebo)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness.","timeFrame":"For 7 days after first vaccination on Day 1 (Up to Day 7)"},{"measure":"Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness.","timeFrame":"For 7 days after second vaccination on Day 29 (Up to Day 35)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events for 7 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited systemic AEs included were for adult participants: fatigue, headache, myalgia, arthralgia, chills, nausea and fever (defined as body temperature \\>=38 degree celsius \\[°C\\]; for pediatric participants: loss of appetite, vomiting, diarrhea, decreased activity/lethargy, irritability/crying and fever (i.e., body temperature \\>=38 °C).","timeFrame":"For 7 days after first vaccination on Day 1 (Up to Day 7)"},{"measure":"Number of Participants With Solicited Systemic Adverse Events for 7 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited systemic AEs included were for adult participants: fatigue, headache, myalgia, arthralgia, chills, nausea and fever (defined as body temperature \\>=38 degree celsius \\[°C\\]; for pediatric participants: loss of appetite, vomiting, diarrhea, decreased activity/lethargy, irritability/crying and fever (i.e., body temperature \\>=38 °C).","timeFrame":"For 7 days after second vaccination on Day 29 (Up to Day 35)"},{"measure":"Number of Participants With Unsolicited Adverse Events for 28 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","timeFrame":"For 28 days after first vaccination on Day 1 (Up to Day 28)"},{"measure":"Number of Participants With Unsolicited Adverse Events for 28 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","timeFrame":"For 28 days after second vaccination on Day 29 (Up to Day 56)"},{"measure":"Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","timeFrame":"From Day 1 (post-vaccination) to end of the study (up to 2 years 4 months)"}],"secondaryOutcomes":[{"measure":"Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers at Days 1, 29, 57 and 211","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","timeFrame":"Day 1 (predose), Post-dose on Days 29, 57 and 211"},{"measure":"Pre-Fusion RSV Fusion Protein (F-protein) Geometric Mean Titers (GMTs) as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) at Days 1, 29, 57 and 211","description":"GMT (ELISA units per liter \\[EU/L\\]) of RSV F protein in pre-fusion form as assessed by ELISA was reported.","timeFrame":"Pre-fusion on Days 1, 29, 57 and 211"},{"measure":"Post-Fusion RSV Fusion Protein (F-protein) Geometric Mean Titers (GMTs) as Assessed by ELISA at Days 1, 29, 57 and 211","description":"GMT (ELISA units per liter \\[EU/L\\]) of RSV F protein in post-fusion form as assessed by ELISA was reported.","timeFrame":"Post-fusion on Days 1, 29, 57 and 211"},{"measure":"Percentage of Cytokine Subsets (CD4, CD8, Th1 and Th2 Cytokines) to Evaluate Total Cytokine Response at Days 1, 29 and 57","description":"Total cytokine response (CD4, CD8, Th1 and Th2 Cytokines) after in vitro RSV F protein peptide stimulation was reported as the percentage of CD4+ and CD8+ T cells that produce at least 1 of 3 cytokines.","timeFrame":"Day 1 (predose) and Post-dose on Days, 29, and 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAdults Participants:\n\n* Participant must be in good health, without significant medical illness, on the basis of physical examination, medical history, and vital signs measurement\n* Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the local laboratory normal reference ranges and additionally within the limits of toxicity Grade 1 according to the United stated (US) Food and Drug Administration (FDA) toxicity tables, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator\n* All women of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin (Beta-hCG) pregnancy test at screening and a negative urine Beta-hCG pregnancy test immediately prior to each study vaccine administration\n\nPediatric Participants:\n\n* Participant is the product of a normal term pregnancy greater than and equal to (\\>=) 37 weeks, with a minimum birth weight of 2.5 kilogram (kg)\n* Participants must be in good health without any significant medical illness on the basis of physical examination, medical history, and vital signs performed at screening\n\nExclusion Criteria:\n\nAdults Participants:\n\n* Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature \\>=38.0 ºC (degree celsius)/100.4 °F (fahrenheit) within 24 hours prior to the first dose of study vaccine\n* Participant has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments\n* Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)\n\nPediatric Participants:\n\n* Participant's weight is below 10th percentile according to World Health Organization (WHO) pediatric growth and weight charts\n* Participant has any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would preclude participation: example, history of seizure disorders, bleeding/clotting disorder, autoimmune disease, active malignancy, systemic infections, congenital heart disease, history of any pulmonary condition requiring medication, atopy, reactive airway disease, medically-confirmed wheezing, bronchoconstriction or treatment with a beta2 agonist, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease, medically-confirmed apnea, hospitalization for respiratory illness, or mechanical ventilation for respiratory illness","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"50 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Janssen Vaccines & Prevention B.V. Clinical Trial","affiliation":"Janssen Vaccines & Prevention B.V.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Heartland Research Associates, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Järvenpään rokotetutkimusklinikka","city":"Jarvenpaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"University of Tampere/Vaccine Research Center","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"University of Tampere/Vaccine Research Center","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Royal Manchester Children's Hospital","city":"Manchester","zip":"M13 9WL","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Oxford Vaccine Group","city":"Oxford","zip":"OX3 7LE","country":"United Kingdom","geoPoint":{"lat":51.75222,"lon":-1.25596}},{"facility":"University Hospital Southampton NHS Foundation Trust","city":"Southampton","zip":"SO166YD","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"FG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"FG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"FG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"BG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"BG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"BG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"48"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"36"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"29"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"19"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"45"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"FINLAND","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"15"}]}]},{"title":"UNITED KINGDOM","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"31"}]}]},{"title":"UNITED STATES","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness.","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 7 days after first vaccination on Day 1 (Up to Day 7)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited local AEs were precisely defined events that participants were specifically asked about and which were noted by participants in the diary. Solicited local AEs included erythema, swelling/induration, and pain/tenderness.","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine. Here, 'N' (number of participant analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 7 days after second vaccination on Day 29 (Up to Day 35)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events for 7 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited systemic AEs included were for adult participants: fatigue, headache, myalgia, arthralgia, chills, nausea and fever (defined as body temperature \\>=38 degree celsius \\[°C\\]; for pediatric participants: loss of appetite, vomiting, diarrhea, decreased activity/lethargy, irritability/crying and fever (i.e., body temperature \\>=38 °C).","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 7 days after first vaccination on Day 1 (Up to Day 7)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"10"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic Adverse Events for 7 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Solicited systemic AEs included were for adult participants: fatigue, headache, myalgia, arthralgia, chills, nausea and fever (defined as body temperature \\>=38 degree celsius \\[°C\\]; for pediatric participants: loss of appetite, vomiting, diarrhea, decreased activity/lethargy, irritability/crying and fever (i.e., body temperature \\>=38 °C).","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine. Here, 'N' (number of participant analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 7 days after second vaccination on Day 29 (Up to Day 35)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"9"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events for 28 Days After First Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 28 days after first vaccination on Day 1 (Up to Day 28)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"8"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events for 28 Days After Second Vaccination","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. Unsolicited adverse events included all adverse events for which the participant is not specifically questioned in the participant diary.","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine. Here, 'N' (number of participant analyzed) signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"For 28 days after second vaccination on Day 29 (Up to Day 56)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with study vaccine. SAE is any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.","populationDescription":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 1 (post-vaccination) to end of the study (up to 2 years 4 months)","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers at Days 1, 29, 57 and 211","description":"RSV A2 strain neutralizing antibody titers of the vaccine-induced immune response was assessed through virus neutralization assay.","populationDescription":"The Per-protocol Immunogenicity (PPI) set included all randomized and vaccinated participants for whom immunogenicity data were available, excluding participant samples with major protocol deviations expecting to impact the immunogenicity outcomes. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified timepoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Day 1 (predose), Post-dose on Days 29, 57 and 211","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Day 1 (pre-dose)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"329","lowerLimit":"252","upperLimit":"431"},{"groupId":"OG001","value":"547","lowerLimit":"86","upperLimit":"3489"},{"groupId":"OG002","value":"121","lowerLimit":"76","upperLimit":"191"},{"groupId":"OG003","value":"187","lowerLimit":"100","upperLimit":"349"}]}]},{"title":"Post dose 1: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1089","lowerLimit":"483","upperLimit":"2456"},{"groupId":"OG001","value":"603","lowerLimit":"101","upperLimit":"3596"},{"groupId":"OG002","value":"1608","lowerLimit":"730","upperLimit":"3544"},{"groupId":"OG003","value":"156","lowerLimit":"68","upperLimit":"358"}]}]},{"title":"Post dose 2: Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"926","lowerLimit":"485","upperLimit":"1769"},{"groupId":"OG001","value":"566","lowerLimit":"114","upperLimit":"2805"},{"groupId":"OG002","value":"2235","lowerLimit":"1586","upperLimit":"3150"},{"groupId":"OG003","value":"198","lowerLimit":"89","upperLimit":"441"}]}]},{"title":"Post dose 2: Day 211","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"704","lowerLimit":"325","upperLimit":"1526"},{"groupId":"OG001","value":"574","lowerLimit":"139","upperLimit":"2374"},{"groupId":"OG002","value":"1164","lowerLimit":"734","upperLimit":"1847"},{"groupId":"OG003","value":"165","lowerLimit":"70","upperLimit":"387"}]}]}]},{"type":"SECONDARY","title":"Pre-Fusion RSV Fusion Protein (F-protein) Geometric Mean Titers (GMTs) as Assessed by Enzyme-linked Immunosorbent Assay (ELISA) at Days 1, 29, 57 and 211","description":"GMT (ELISA units per liter \\[EU/L\\]) of RSV F protein in pre-fusion form as assessed by ELISA was reported.","populationDescription":"The PPI set included all randomized and vaccinated participants for whom immunogenicity data were available, excluding participant samples with major protocol deviations expecting to impact the immunogenicity outcomes. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified timepoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/L","timeFrame":"Pre-fusion on Days 1, 29, 57 and 211","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"197","lowerLimit":"132","upperLimit":"295"},{"groupId":"OG001","value":"249","lowerLimit":"50","upperLimit":"1234"},{"groupId":"OG002","value":"59","lowerLimit":"36","upperLimit":"97"},{"groupId":"OG003","value":"113","lowerLimit":"57","upperLimit":"223"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"441","lowerLimit":"304","upperLimit":"639"},{"groupId":"OG001","value":"261","lowerLimit":"60","upperLimit":"1138"},{"groupId":"OG002","value":"1174","lowerLimit":"524","upperLimit":"2630"},{"groupId":"OG003","value":"106","lowerLimit":"56","upperLimit":"199"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"481","lowerLimit":"317","upperLimit":"729"},{"groupId":"OG001","value":"244","lowerLimit":"60","upperLimit":"992"},{"groupId":"OG002","value":"1918","lowerLimit":"1497","upperLimit":"2456"},{"groupId":"OG003","value":"148","lowerLimit":"54","upperLimit":"402"}]}]},{"title":"Day 211","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"418","lowerLimit":"264","upperLimit":"664"},{"groupId":"OG001","value":"292","lowerLimit":"45","upperLimit":"1895"},{"groupId":"OG002","value":"924","lowerLimit":"639","upperLimit":"1334"},{"groupId":"OG003","value":"120","lowerLimit":"39","upperLimit":"370"}]}]}]},{"type":"SECONDARY","title":"Post-Fusion RSV Fusion Protein (F-protein) Geometric Mean Titers (GMTs) as Assessed by ELISA at Days 1, 29, 57 and 211","description":"GMT (ELISA units per liter \\[EU/L\\]) of RSV F protein in post-fusion form as assessed by ELISA was reported.","populationDescription":"The PPI set included all randomized and vaccinated participants for whom immunogenicity data were available, excluding participant samples with major protocol deviations expecting to impact the immunogenicity outcomes. Here, 'n' (number analyzed) signifies the number of participants evaluable at a specified timepoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/L","timeFrame":"Post-fusion on Days 1, 29, 57 and 211","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"196","lowerLimit":"112","upperLimit":"346"},{"groupId":"OG001","value":"191","lowerLimit":"19","upperLimit":"1879"},{"groupId":"OG002","value":"77","lowerLimit":"48","upperLimit":"125"},{"groupId":"OG003","value":"94","lowerLimit":"46","upperLimit":"190"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"328","lowerLimit":"207","upperLimit":"521"},{"groupId":"OG001","value":"207","lowerLimit":"25","upperLimit":"1738"},{"groupId":"OG002","value":"686","lowerLimit":"371","upperLimit":"1268"},{"groupId":"OG003","value":"86","lowerLimit":"47","upperLimit":"158"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"341","lowerLimit":"198","upperLimit":"589"},{"groupId":"OG001","value":"179","lowerLimit":"23","upperLimit":"1370"},{"groupId":"OG002","value":"863","lowerLimit":"630","upperLimit":"1184"},{"groupId":"OG003","value":"109","lowerLimit":"52","upperLimit":"232"}]}]},{"title":"Day 211","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"268","lowerLimit":"142","upperLimit":"507"},{"groupId":"OG001","value":"181","lowerLimit":"18","upperLimit":"1870"},{"groupId":"OG002","value":"420","lowerLimit":"306","upperLimit":"576"},{"groupId":"OG003","value":"91","lowerLimit":"33","upperLimit":"256"}]}]}]},{"type":"SECONDARY","title":"Percentage of Cytokine Subsets (CD4, CD8, Th1 and Th2 Cytokines) to Evaluate Total Cytokine Response at Days 1, 29 and 57","description":"Total cytokine response (CD4, CD8, Th1 and Th2 Cytokines) after in vitro RSV F protein peptide stimulation was reported as the percentage of CD4+ and CD8+ T cells that produce at least 1 of 3 cytokines.","populationDescription":"PPI set: all randomized and vaccinated participants for whom immunogenicity data were available, excluding participant samples with major protocol deviations expecting to impact immunogenicity outcomes. 'N' (number of participants analyzed)=number of participants who were evaluable for this outcome measure, 'n' (number analyzed)=number of participants evaluable at specified timepoint and '0' in number analyzed field=none of participants were applicable for evaluation at specified time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Percentage of cytokine cell subsets","timeFrame":"Day 1 (predose) and Post-dose on Days, 29, and 57","groups":[{"id":"OG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29."},{"id":"OG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29."},{"id":"OG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29."},{"id":"OG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"8"}]}],"classes":[{"title":"CD4: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","lowerLimit":"0.057","upperLimit":"0.067"},{"groupId":"OG001","value":"0.054","lowerLimit":"0.048","upperLimit":"0.108"},{"groupId":"OG002","value":"0.030","lowerLimit":"0.013","upperLimit":"0.095"},{"groupId":"OG003","value":"0.050","lowerLimit":"0.015","upperLimit":"0.079"}]}]},{"title":"CD4: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.168","lowerLimit":"0.100","upperLimit":"0.210"},{"groupId":"OG001","value":"0.058","lowerLimit":"0.051","upperLimit":"0.082"},{"groupId":"OG002","value":"0.089","lowerLimit":"0.062","upperLimit":"0.131"},{"groupId":"OG003","value":"0.074","lowerLimit":"0.056","upperLimit":"0.123"}]}]},{"title":"CD4: Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.148","lowerLimit":"0.115","upperLimit":"0.351"},{"groupId":"OG001","value":"0.039","lowerLimit":"0.024","upperLimit":"0.116"}]}]},{"title":"CD8: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.041","lowerLimit":"0.033","upperLimit":"0.084"},{"groupId":"OG001","value":"0.075","lowerLimit":"0.005","upperLimit":"0.141"},{"groupId":"OG002","value":"0.033","lowerLimit":"0.024","upperLimit":"0.049"},{"groupId":"OG003","value":"0.041","lowerLimit":"0.025","upperLimit":"0.081"}]}]},{"title":"CD8: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.145","lowerLimit":"0.080","upperLimit":"0.233"},{"groupId":"OG001","value":"0.092","lowerLimit":"0.022","upperLimit":"0.105"},{"groupId":"OG002","value":"0.077","lowerLimit":"0.024","upperLimit":"0.116"},{"groupId":"OG003","value":"0.053","lowerLimit":"0.016","upperLimit":"0.110"}]}]},{"title":"CD8: Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.081","lowerLimit":"0.070","upperLimit":"0.211"},{"groupId":"OG001","value":"0.062","lowerLimit":"0.003","upperLimit":"0.185"}]}]},{"title":"Th1: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","lowerLimit":"0.028","upperLimit":"0.065"},{"groupId":"OG001","value":"0.054","lowerLimit":"0.031","upperLimit":"0.096"},{"groupId":"OG002","value":"0.007","lowerLimit":"0.003","upperLimit":"0.022"},{"groupId":"OG003","value":"0.018","lowerLimit":"0.011","upperLimit":"0.027"}]}]},{"title":"Th1: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.098","lowerLimit":"0.040","upperLimit":"0.146"},{"groupId":"OG001","value":"0.049","lowerLimit":"0.037","upperLimit":"0.057"},{"groupId":"OG002","value":"0.034","lowerLimit":"0.025","upperLimit":"0.078"},{"groupId":"OG003","value":"0.028","lowerLimit":"0.017","upperLimit":"0.055"}]}]},{"title":"Th1: Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.112","lowerLimit":"0.083","upperLimit":"0.302"},{"groupId":"OG001","value":"0.039","lowerLimit":"0.008","upperLimit":"0.061"}]}]},{"title":"Th2: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","lowerLimit":"0.001","upperLimit":"0.016"},{"groupId":"OG001","value":"0.001","lowerLimit":"0.001","upperLimit":"0.002"},{"groupId":"OG002","value":"0.002","lowerLimit":"0.001","upperLimit":"0.004"},{"groupId":"OG003","value":"0.004","lowerLimit":"0.001","upperLimit":"0.005"}]}]},{"title":"Th2: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","lowerLimit":"0.002","upperLimit":"0.006"},{"groupId":"OG001","value":"0.001","lowerLimit":"0.001","upperLimit":"0.001"},{"groupId":"OG002","value":"0.005","lowerLimit":"0.001","upperLimit":"0.007"},{"groupId":"OG003","value":"0.003","lowerLimit":"0.002","upperLimit":"0.007"}]}]},{"title":"Th2: Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.003","lowerLimit":"0.001","upperLimit":"0.022"},{"groupId":"OG001","value":"0.001","lowerLimit":"0.001","upperLimit":"0.001"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From Day 1 (post-vaccination) up to end of the study (up to 2 years 4 months)","description":"The safety analysis set included all participants who were randomized and received at least 1 dose of study vaccine.","eventGroups":[{"id":"EG000","title":"Cohort 0 (Adults): Ad26.RSV.preF","description":"Adult participants aged greater than or equal to (\\>=) 18 years to less than or equal to (\\<=) 50 years received a single intramuscular (IM) injection of adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) at dose of 1\\*10\\^11 viral particles (vp) on Day 1 and Day 29.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":6,"otherNumAtRisk":8},{"id":"EG001","title":"Cohort 0 (Adults): Placebo","description":"Adult participants aged \\>=18 years to \\<=50 years received a single IM injection of placebo matching to Ad26.RSV.preF (1\\*10\\^11 vp) on Day 1 and Day 29.","deathsNumAffected":0,"deathsNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"otherNumAffected":1,"otherNumAtRisk":4},{"id":"EG002","title":"Cohort 1 (Toddlers): Ad26.RSV.preF","description":"Respiratory syncytial virus (RSV) seropositive toddler participants aged \\>=12 to \\<=24 months received a single IM injection of Ad26.RSV.preF at dose of 5\\*10\\^10 vp on Day 1 and Day 29.","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":1,"seriousNumAtRisk":24,"otherNumAffected":19,"otherNumAtRisk":24},{"id":"EG003","title":"Cohort 1 (Toddlers): Placebo","description":"RSV seropositive toddler participants received a single IM injection of placebo matching to Ad26.RSV.preF (5\\*10\\^10 vp) on Day 1 and Day 29.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":2,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]}],"otherEvents":[{"term":"Abdominal Discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":2,"numAtRisk":12}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Teething","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Influenza Like Illness","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Allergy to Animal","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Anal Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Body Tinea","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Enterovirus Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Hand-Foot-And-Mouth Disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Oral Herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Otitis Externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Otitis Media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":4,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":4,"numAtRisk":24},{"groupId":"EG003","numAffected":4,"numAtRisk":12}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":2,"numAtRisk":12}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Skin Bacterial Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Tinea Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":8,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Viral Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Viral Rash","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Viral Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":2,"numAtRisk":12}]},{"term":"Heart Rate Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Influenza B Virus Test Positive","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Lymphocyte Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Respiratory Syncytial Virus Test Positive","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Loss of Consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":2,"numAtRisk":12}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":2,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Rales","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Respiratory Tract Irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Rhonchi","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Dermatitis Diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":1,"numAtRisk":12}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":1,"numAtRisk":4},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 22.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":8},{"groupId":"EG001","numAffected":0,"numAtRisk":4},{"groupId":"EG002","numAffected":1,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days."},"pointOfContact":{"title":"Trial Physician","organization":"Janssen Vaccines and Prevention B.V.","email":"ClinicalTrialDisclosure@its.jnj.com","phone":"844-434-4210"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-04-18","uploadDate":"2023-04-19T04:20","filename":"Prot_000.pdf","size":3197848},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-04-25","uploadDate":"2023-04-19T04:20","filename":"SAP_001.pdf","size":1296935}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-05-15","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D012141","term":"Respiratory Tract Infections"}],"ancestors":[{"id":"D007239","term":"Infections"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}